0001356576 false 0001356576 2021-11-24 2021-11-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549





Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): November 24, 2021


Supernus Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)


Delaware 001-35518 20-2590184

(State or other jurisdiction of

incorporation or organization)

(Commission File Number) (I.R.S. Employer Identification No.)


9715 Key West Ave Rockville MD 20850

(Address of Principal Executive


    (Zip Code)


Registrant’s telephone number, including area code: (301) 838-2500


Not Applicable

(Former name or former address, if changed since last report.)


Securities registered pursuant to Section 12(b) of the Exchange Act


Title of each class Trading Symbol Name of each exchange on which registered
Common Stock, $0.001 par value per share SUPN The Nasdaq Stock Market LLC


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 8.01 Other Events.


On November 24, 2021, Supernus Pharmaceuticals, Inc. (the “Company”) issued a press release regarding a recent ransomware incident. The incident had no significant impact on the Company’s business and did not cause any serious disruption to the Company’s operations. A copy of the press release is filed as Exhibit 99.1 hereto, and the text of such press release is incorporated herein by reference.


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits


Exhibit Description
99.1 Press Release dated November 24, 2021.
104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).







Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: November 24, 2021 By: /s/ Timothy C. Dec
  Name: Timothy C. Dec
  Title: Senior Vice President and Chief Financial Officer





Exhibit 99.1




Supernus Pharmaceuticals Targeted in Ransomware Incident


The attack had no significant impact on the business and did not cause any significant disruption to Company’s operations


No ransom payments have been made by the Company


ROCKVILLE, Md., Nov. 24, 2021 -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company, today announced that it was the recent target of a ransomware attack. The attack had no significant impact on the business and did not cause any serious disruption to the Company’s operations. The Company continues to operate without interruption and does not currently anticipate paying any ransom amounts to any criminal ransomware group.


The Company currently believes the incident began around mid-November, 2021. Based on the preliminary results of the ongoing investigation, the Company believes the criminal ransomware group encrypted certain files on the Company’s systems, deployed malware to impede access to the Company’s systems, and thereafter threatened to publish certain data copied from the Company’s systems. Upon detection of the ransomware, the Company notified government authorities, engaged cybersecurity experts and its outside law firm, and commenced its recovery process. The Company successfully recovered the impacted files and has taken additional steps designed to further protect its networks and files.


To date, the Company has not paid any ransom and has been able to restore all of the information encrypted by the criminal ransomware group.


Although to date the Company’s business and operations have not been significantly impacted by the incident, there is no assurance that further attacks may not significantly impact the Company’s business or operations and that information improperly obtained by the criminal ransomware group may not be exploited by the criminal ransomware group or other third parties. The Company will take appropriate action to protect any stolen confidential information and will continue to investigate the incident and monitor the situation going forward.


About Supernus Pharmaceuticals, Inc.


Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.


Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease, cervical dystonia and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in Parkinson’s disease, epilepsy, depression and rare CNS disorders.


For more information, please visit www.supernus.com.






Jack A. Khattar, President and CEO 

Timothy C. Dec, Senior Vice President and CFO 

Supernus Pharmaceuticals, Inc. 

Tel: (301) 838-2591






Peter Vozzo 

ICR Westwicke 

Office: (443) 213-0505 

Mobile: (443) 377-4767 

Email: peter.vozzo@westwicke.com